- Sort by Popularity (sales)
- Display 15 Products per page
Congestive Heart Failure – Major World Markets, Volume II – Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)
Published: February 1, 2008 | Price: $995.00 – $1,990.00
Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure. Kalorama Information's Congestive Heart Failure, Major World Markets series looks at markets for...
Pharmaceutical Excipients for Oral Formulations, 2nd. Edition
Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...
Congestive Heart Failure – Major World Markets, Volume I – Pharmaceutical Management
Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...
Gene Expression Profiling Markets
Published: January 1, 2008 | Price: $995.00 – $7,990.00
Parts of the gene expression analysis market continue to develop in a somewhat predictable manner, whereas other segments are becoming increasingly complex and volatile. The main products—microarrays and RT-PCR—continue to gain widespread acceptance and to see revenues grow rapidly. However, different products and applications are increasingly being introduced, making the market more fragmented as well as unpredictable. In terms of application, too, the landscape is shifting. Although life-science research is still the dominant application, the clinical diagnostics and prognostics market...
Prescription Dermatological Drugs: Worldwide Market, 6th Edition
Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...
Organ Transplant Immunosuppressive Markets
Published: January 1, 2008 | Price: $995.00 – $1,990.00
Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used....
Pediatric Drugs: the Worldwide Market, 3rd Edition
Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...
Worldwide Market for Rheumatoid Arthritis and Lupus Treatments ( Autoimmune Disease Markets )
Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...
World Cardiovascular Drug Market, (Antihypertensives, Antihyperlipidemics, Vasodilators, Anticoagulants, Diuretics and other Agents) , The
Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...
Contract Manufacturing in Medical Devices (Raw Materials, Electronics and Finished Products Markets)
Published: November 1, 2007 | Price: $3,800.00 – $13,990.00
The trend of medical device outsourcing, or contract manufacturing is increasing. This Kalorama Information report takes an exhaustive look at the total market of OEMs outsourcing device manufacture to CMs. This publication represents the total OEM contract manufacturing market - it is the combination of three volumes in Kalorama Information's OEM Contract Manufacturing in Medical Devices Series. (The publication is combined for PDF delivery and hard copy delivery would come in three seperate volumes) For electronic delivery, a special overview...
Growing “Out of Pocket” Healthcare Market (Spending on Surgeries, Pharmaceuticals and Other Healthcare Services), The
Published: November 1, 2007 | Price: $3,250.00 – $6,500.00
While insurance is the most common form of payment for healthcare services, increasingly customers are paying for their own expenses. Pharmaceutical, device and diagnostic companies, should recognize that a part of their revenues are originating directly or indirectly from out of pocket expenditures. Health care costs are high and accelerating as a result of a confluence of factors within the broader economy, as well as the health care marketplace. Unique financial services have been created to facilitate non-insurance-paid health care...
Offshoring Clinical Trials (The Market for Clinical Trials in India, China, Mexico, Brazil, Russia and Israel.)
Published: November 1, 2007 | Price: $1,500.00 – $7,000.00
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...
Analytical Chip Technology – U.S. Markets for Lab on a Chip, DNA/Gene, Protein, and other Microarrays, 3rd. Edition
Published: November 1, 2007 | Price: $995.00 – $5,495.00
Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad — covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. Kalorama's Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein and other Microarrasys) 3rd. Edition looks at the market for analytical microchips with a unique methodology -- the market is expressed...
Cell-Based Diagnostics – Technology, Applications, and Markets, 2nd Edition
Published: November 1, 2007 | Price: $1,995.00 – $3,990.00
No longer is cell-based diagnostics simply a histological study of biopsied and surgical tissues. Combinations of tests and technologies are coming together to create a new map of cell diagnostics. Image cytometry, microfluidics, microarrays, and biosensors, special immunohistochemical and in situ hybridization probes are creating new approaches to cell and tissue observation, diagnostics and pharmacogenomics. This report covers assay systems that use cells as the basic source material. Sources of the cells to be studied include peripheral blood, cord blood,...
OEM Contract Manufacturing in Medical Devices, World Market, Vol III – Finished Clinical Products and Systems
Published: November 1, 2007 | Price: $1,995.00 – $6,990.00
Contract Manufacturers are finding opportunities with managers located at OEM corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. Once satisfied with outsourcing only a small part of operations, OEM companies are now looking to CMs for finished products and finished computer systems. The highly skilled firms who compete in this area meet the challenges of overburdened OEM device companies demanding a ready-to-launch product. Kalorama's OEM Contract Manufacturing in...